|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2002-12-10
|
|
pubmed:abstractText |
2-Methoxyestradiol (2ME2), a natural endogenous product of estradiol metabolism, has demonstrated activity against tumor cell lines and can inhibit angiogenesis. There are limited treatment options for patients with multiple myeloma (MM) who relapse after high-dose therapy and stem cell transplantation. We studied the preclinical activity of 2ME2 as a therapeutic agent for myeloma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3948-54
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12473611-Animals,
pubmed-meshheading:12473611-Apoptosis,
pubmed-meshheading:12473611-Cell Division,
pubmed-meshheading:12473611-Drug Evaluation, Preclinical,
pubmed-meshheading:12473611-Drug Resistance, Neoplasm,
pubmed-meshheading:12473611-Drug Screening Assays, Antitumor,
pubmed-meshheading:12473611-Estradiol,
pubmed-meshheading:12473611-Humans,
pubmed-meshheading:12473611-Mice,
pubmed-meshheading:12473611-Mice, SCID,
pubmed-meshheading:12473611-Multiple Myeloma,
pubmed-meshheading:12473611-Neoplasms, Experimental,
pubmed-meshheading:12473611-Plasma Cells,
pubmed-meshheading:12473611-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
|
|
pubmed:affiliation |
Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
